Skip to main content
. 2017 Sep 18;8(58):98215–98232. doi: 10.18632/oncotarget.21003

Figure 2. Stimulation of PBMCs by α-CD3/CD28 in the presence of atorvastatin results in reduced expression of co-inhibitory receptors by CD4+ and CD8+ T cells.

Figure 2

(A) Downregulation in co-inhibitory receptor expression by stimulated T cells in response to atorvastatin treatment occurs over time in a dose-dependent manner. Percentages of PD-1, LAG-3 and CD160 expressed by CD4+ (left) and CD8+ (right) T cells in response to α-CD3/CD28 stimulation in the presence of the indicated concentrations of atorvastatin after 24, 48 and 72hrs. Data from three independent experiments shown. (B) Bar graphs showing cumulative expression of PD1, LAG-3, TIM-3, CD160, CTLA-4 and CD244 by CD4+ and CD8+ T cells stimulated with α-CD3/CD28 with or without atorvastatin (1 μg/ml) for 48hrs. Unstimulated (cells only) cultures were used as negative controls. P values are defined by * (P ≤ 0.05) ** (P < 0.01), *** (P < 0.001) and **** (P < 0.0001).